These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

326 related articles for article (PubMed ID: 28243404)

  • 1. Effect of Persian Medicine Remedy on Chemotherapy Induced Nausea and Vomiting in Breast Cancer: A Double Blind, Randomized, Crossover Clinical Trial.
    Nazari M; Taghizadeh A; Bazzaz MM; Rakhshandeh H; Shokri S
    Electron Physician; 2017 Jan; 9(1):3535-3543. PubMed ID: 28243404
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A randomized, double-blind, placebo-controlled study evaluating the efficacy of combination olanzapine, ondansetron and dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving doxorubicin plus cyclophosphamide.
    Tienchaiananda P; Nipondhkit W; Maneenil K; Sa-Nguansai S; Payapwattanawong S; Laohavinij S; Maneechavakajorn J
    Ann Palliat Med; 2019 Sep; 8(4):372-380. PubMed ID: 31500422
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of auricular acupressure on chemotherapy-induced nausea and vomiting in breast cancer patients: a preliminary randomized controlled trial.
    Tan JY; Molassiotis A; Suen LKP; Liu J; Wang T; Huang HR
    BMC Complement Med Ther; 2022 Mar; 22(1):87. PubMed ID: 35331208
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Effect of Foot Reflexology on Chemotherapy-Induced Nausea and Vomiting in Patients With Digestive or Lung Cancer: Randomized Controlled Trial.
    Murat-Ringot A; Souquet PJ; Subtil F; Boutitie F; Preau M; Piriou V
    JMIR Cancer; 2021 Nov; 7(4):e25648. PubMed ID: 34738909
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevention of delayed chemotherapy-induced nausea and vomiting after moderately high to highly emetogenic chemotherapy: comparison of ondansetron, prochlorperazine, and dexamethasone.
    Lindley C; Goodin S; McCune J; Kane M; Amamoo MA; Shord S; Pham T; Yowell S; Laliberte K; Schell M; Bernard S; Socinski MA
    Am J Clin Oncol; 2005 Jun; 28(3):270-6. PubMed ID: 15923800
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Can treatment with Cocculine improve the control of chemotherapy-induced emesis in early breast cancer patients? A randomized, multi-centered, double-blind, placebo-controlled Phase III trial.
    Pérol D; Provençal J; Hardy-Bessard AC; Coeffic D; Jacquin JP; Agostini C; Bachelot T; Guastalla JP; Pivot X; Martin JP; Bajard A; Ray-Coquard I
    BMC Cancer; 2012 Dec; 12():603. PubMed ID: 23244208
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aprepitant: a review of its use in the prevention of chemotherapy-induced nausea and vomiting.
    Dando TM; Perry CM
    Drugs; 2004; 64(7):777-94. PubMed ID: 15025555
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of triplet regimen antiemetic therapy for chemotherapy-induced nausea and vomiting (CINV) in bone and soft tissue sarcoma patients receiving highly emetogenic chemotherapy, and an efficacy comparison of single-shot palonosetron and consecutive-day granisetron for CINV in a randomized, single-blinded crossover study.
    Kimura H; Yamamoto N; Shirai T; Nishida H; Hayashi K; Tanzawa Y; Takeuchi A; Igarashi K; Inatani H; Shimozaki S; Kato T; Aoki Y; Higuchi T; Tsuchiya H
    Cancer Med; 2015 Mar; 4(3):333-41. PubMed ID: 25533447
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oral THC:CBD cannabis extract for refractory chemotherapy-induced nausea and vomiting: a randomised, placebo-controlled, phase II crossover trial.
    Grimison P; Mersiades A; Kirby A; Lintzeris N; Morton R; Haber P; Olver I; Walsh A; McGregor I; Cheung Y; Tognela A; Hahn C; Briscoe K; Aghmesheh M; Fox P; Abdi E; Clarke S; Della-Fiorentina S; Shannon J; Gedye C; Begbie S; Simes J; Stockler M
    Ann Oncol; 2020 Nov; 31(11):1553-1560. PubMed ID: 32801017
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Testing the effectiveness of antiemetic guidelines: results of a prospective registry by the CINV Study Group of Japan.
    Tamura K; Aiba K; Saeki T; Nakanishi Y; Kamura T; Baba H; Yoshida K; Yamamoto N; Kitagawa Y; Maehara Y; Shimokawa M; Hirata K; Kitajima M;
    Int J Clin Oncol; 2015 Oct; 20(5):855-65. PubMed ID: 25681876
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chemotherapy-Induced Nausea and Vomiting (CINV) with GI Cancer Chemotherapy: Do We Need CINV Risk Score Over and Above Antiemetic Guidelines in Prescribing Antiemetic Regime?
    D'Souza A; Pawar D; Ramaswamy A; Turkar S; Bhargava P; Kapoor A; Mandavkar S; Nashikkar C; Ostwal V
    South Asian J Cancer; 2020 Oct; 9(4):240-244. PubMed ID: 34131576
    [No Abstract]   [Full Text] [Related]  

  • 12. Incidence of chemotherapy-induced nausea and vomiting in Taiwan: physicians' and nurses' estimation vs. patients' reported outcomes.
    Liau CT; Chu NM; Liu HE; Deuson R; Lien J; Chen JS
    Support Care Cancer; 2005 May; 13(5):277-86. PubMed ID: 15770489
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A randomized study of aprepitant, ondansetron and dexamethasone for chemotherapy-induced nausea and vomiting in Chinese breast cancer patients receiving moderately emetogenic chemotherapy.
    Yeo W; Mo FK; Suen JJ; Ho WM; Chan SL; Lau W; Koh J; Yeung WK; Kwan WH; Lee KK; Mok TS; Poon AN; Lam KC; Hui EK; Zee B
    Breast Cancer Res Treat; 2009 Feb; 113(3):529-35. PubMed ID: 18327706
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Amisulpride prevents nausea and vomiting associated with highly emetogenic chemotherapy: a randomised, double-blind, placebo-controlled, dose-ranging trial.
    Herrstedt J; Summers Y; Jordan K; von Pawel J; Jakobsen AH; Ewertz M; Chan S; Naik JD; Karthaus M; Dubey S; Davis R; Fox GM
    Support Care Cancer; 2019 Jul; 27(7):2699-2705. PubMed ID: 30488222
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Late chronotypes are associated with neoadjuvant chemotherapy-induced nausea and vomiting in women with breast cancer.
    Lee KM; Jung DY; Hwang H; Kim WH; Lee JY; Kim TY; Im SA; Lee KH; Spiegel D; Hahm BJ
    Chronobiol Int; 2017; 34(4):480-491. PubMed ID: 28362229
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Poor chemotherapy-induced nausea and vomiting control in children receiving intermediate or high dose methotrexate.
    Vol H; Flank J; Lavoratore SR; Nathan PC; Taylor T; Zelunka E; Maloney AM; Lee Dupuis L
    Support Care Cancer; 2016 Mar; 24(3):1365-71. PubMed ID: 26335406
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a double-blind, double-dummy, randomised, comparative phase III trial.
    Saito M; Aogi K; Sekine I; Yoshizawa H; Yanagita Y; Sakai H; Inoue K; Kitagawa C; Ogura T; Mitsuhashi S
    Lancet Oncol; 2009 Feb; 10(2):115-24. PubMed ID: 19135415
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk Model-Guided Antiemetic Prophylaxis vs Physician's Choice in Patients Receiving Chemotherapy for Early-Stage Breast Cancer: A Randomized Clinical Trial.
    Clemons M; Bouganim N; Smith S; Mazzarello S; Vandermeer L; Segal R; Dent S; Gertler S; Song X; Wheatley-Price P; Dranitsaris G
    JAMA Oncol; 2016 Feb; 2(2):225-31. PubMed ID: 26562292
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chemotherapy-induced nausea and vomiting (CINV) in 190 colorectal cancer patients: a prospective registration study by the CINV study group of Japan.
    Tsuji Y; Baba H; Takeda K; Kobayashi M; Oki E; Gotoh M; Yoshida K; Shimokawa M; Kakeji Y; Aiba K
    Expert Opin Pharmacother; 2017 Jun; 18(8):753-758. PubMed ID: 28395603
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Palonosetron versus other 5-HT(3) receptor antagonists for prevention of chemotherapy-induced nausea and vomiting in patients with cancer on chemotherapy in a hospital outpatient setting.
    Balu S; Buchner D; Craver C; Gayle J
    Clin Ther; 2011 Apr; 33(4):443-55. PubMed ID: 21635990
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.